|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The rare congenital bleeding disorders are a heterogeneous group of diseases which include deficiencies of fibrinogen, prothrombin and factors V, V + VIII, VII, X, XI and XIII.
|
30306070 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Coagulopathy due to warfarin in patients with major bleeding was traditionally reversed with fresh frozen plasma and intravenous (IV) vitamin K, but prothrombin complex concentrates (PCC) are increasingly used in the treatment of these patients.
|
31176578 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Rats subjected to polytrauma and hemorrhage develop a coagulopathy that is similar to acute coagulopathy of trauma in humans, and is associated with a rise in prothrombin time and a fall in clot strength.
|
31090681 |
2020 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The patients were classified in the clinically unstable group if at least 1 of the following conditions was observed upon admission in the ED: hypoxia requiring oxygen supplementation, hypotension requiring inotropic support, coagulopathy with prothrombin time (international normalized ratio, ≥1.5), and seizures or altered consciousness.
|
29794953 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Tigecycline-induced coagulopathy usually manifests as the dose-dependent prolongation of prothrombin time and activated partial thromboplastin time and a reduction in the fibrinogen level.
|
31713108 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Platelet prothrombinase activity and microvesicle (MV) generation were measured in four patients from three unrelated families with a life-long bleeding disorder associated with slightly prolonged bleeding time and isolated defective serum prothrombin consumption, without platelet function abnormality or von Willebrand factor defect.
|
9054648 |
1997 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: A propensity matched analysis.
|
29664892 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The objective of this study was to analyse the effect of the temperature and the storage of plasma sample on Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) in clinical samples for 65 patients without coagulation disorders.
|
30868948 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Intravenous (IV) prothrombin complex concentrate (PCC) may reverse VKA-induced coagulopathy in <30 min.
|
31060844 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
CYP2C9 and VKORC1 genetic polymorphism analysis might be necessary in patients with Factor V Leiden and prothrombin gene G2021A mutation(s).
|
17721328 |
2007 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The original patient with prothrombin Denver had a severe haemophilia-like bleeding disorder treated with weekly prophylactic factor replacement.
|
10651742 |
2000 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma.
|
29661410 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
They have demonstrated that a prothrombin defect may be associated with thrombosis, that a mild bleeding tendency may occur despite normal Factor V levels and that high levels of plasmatic thrombomodulin may be associated with mild bleeding.
|
31793409 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The haemostatic effect of 2, 4 and 8 mg/kg recombinant prothrombin (MEDI8111) co-administered with 100 mg/kg fibrinogen (n = 7-8) was investigated in a porcine model of dilutional coagulopathy with uncontrolled bleeding.
|
31090596 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Recombinant human prothrombin reduced blood loss in a porcine model of dilutional coagulopathy with uncontrolled bleeding.
|
27428015 |
2017 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
There was no significant increase in coagulopathy in any group as suggested by comparable chest tube drainage ( P = 0.285) and comparable prothrombin time.
|
28062681 |
2017 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The patient's presumed AMR, cardiogenic shock, and coagulopathy were treated with extracorporeal membrane oxygenation (ECMO), plasmapheresis, intravenous immunoglobulin (IVIG), multiple blood products, and prothrombin complex concentrate.
|
31400258 |
2020 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
On admission, laboratory assays showed severe coagulopathy of unknown cause; the patient was empirically treated using a multimodal hemostatic approach with prothrombin complex concentrate, fresh-frozen plasma, and tranexamic acid.
|
30964547 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Prothrombin complex concentrates (PCC) provide concentrated coagulation factors which may reverse coagulopathy more quickly than plasma (FFP) alone.
|
29392436 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and postsurgery hemorrhages.
|
30559262 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
He experienced coagulopathy and hypofibrinogenemia as substantiated by increased levels of prolonged prothrombin time (PT), the international normalized ratio (INR) and activated partial thromboplastin time (APTT), and in particular, the fibrinogen (FIB) levels obviously decreased.
|
29245350 |
2017 |
|
Blood Coagulation Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Prothrombin time and activated partial thromboplastin time were slightly prolonged in 10 patients (7.1%) because of mild coagulation factor deficiencies, which were not responsible for the bleeding diathesis. von Willebrand factor antigen, ristocetin cofactor, endogenous thrombin potential and platelet count were normal in all patients.
|
30312027 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The dose of warfarin required to maintain the prothrombin time in a range of 1.8 to 2.2 times normal varied considerably during short periods, a phenomenon that may have been due to several factors: hypercatabolism of the drug with prolonged administration, abnormality of liver function, variation in levels of serum albumin, fluctuations in drug dosage secondary to oral administration, and variations in dietary vitamin K. Protein C determinations by immunologic and functional assays consistently showed detectable but reduced protein C antigen levels with undetectable activity levels, suggesting that a dysproteinemia rather than a deficiency of synthesis is responsible for the child's coagulopathy.
|
3340476 |
1988 |
|
Blood Coagulation Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Coagulation studies in a 50-yr-old French woman without bleeding tendency revealed the following results: whole-blood clotting time in glass tubes and activated partial thromboplastin time with kaolin and ellagic acid were greatly prolonged; one-stage prothrombin was normal; no circulating anticoagulant was detected, and the infusion of normal plasma corrected the coagulation defect with an estimated half-life of 6.5 days; the levels of factor VIII, IX, XI, and XII were normal; mutual correction was obtained with a Fletcher factor-deficient plasma; the level of whole complement was normal.
|
1174709 |
1975 |
|
Blood Coagulation Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Thrombophilia screening showed a mutant prothrombin 20210A allele which is an inherited coagulopathy associated with increased plasma levels of prothrombin and increased risks of mainly venous thrombosis.
|
10894919 |
2000 |